Read Gene
Read-Gene S.A. is a pioneering biotechnology company dedicated to genetic research, testing, and clinical trials aimed at cancer prevention and treatment through personalized medicine. The company actively participates in clinical trials, develops innovative genetic tests, and holds patents for novel diagnostic methods. Its mission is to improve health outcomes by leveraging advanced genetic analysis and research.
Industries
Nr. of Employees
small (1-50)
Read Gene
Grzepnica, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska)
Products
Packaged trace‑element panels (3‑element and 6‑element options)
Predefined laboratory test panels measuring selected trace elements in blood or serum with interpretive reporting and recommendations based on cohort‑derived norms.
Packaged trace‑element panels (3‑element and 6‑element options)
Predefined laboratory test panels measuring selected trace elements in blood or serum with interpretive reporting and recommendations based on cohort‑derived norms.
Services
Quantitative measurement of trace elements in whole blood and serum using ICP‑MS, with interpretive reporting, matrix‑specific reference comparisons and participation in external QA programs.
Laboratory services for germline variant detection and multi‑gene hereditary cancer panels, including high‑depth sequencing, reporting and reflex copy‑number analysis.
Development and provision of tests integrating blood/serum trace‑element concentrations with targeted genotyping to estimate individual disease risk and support referral decisions.
Management of participant registries and longitudinal biospecimen collections with linkage to national mortality and administrative registries to support outcome and survival analyses.
Design, operational support and recruitment for clinical studies requiring genetic stratification, leveraging maintained registries and biobanks for accelerated enrollment.
On‑site clinical trial operations for oncology studies and coordination of interventional trials, including protocol implementation, patient visits and sponsor liaison.
Quantitative measurement of trace elements in whole blood and serum using ICP‑MS, with interpretive reporting, matrix‑specific reference comparisons and participation in external QA programs.
Laboratory services for germline variant detection and multi‑gene hereditary cancer panels, including high‑depth sequencing, reporting and reflex copy‑number analysis.
Development and provision of tests integrating blood/serum trace‑element concentrations with targeted genotyping to estimate individual disease risk and support referral decisions.
Management of participant registries and longitudinal biospecimen collections with linkage to national mortality and administrative registries to support outcome and survival analyses.
Design, operational support and recruitment for clinical studies requiring genetic stratification, leveraging maintained registries and biobanks for accelerated enrollment.
On‑site clinical trial operations for oncology studies and coordination of interventional trials, including protocol implementation, patient visits and sponsor liaison.
Expertise Areas
- Trace‑element biomarker measurement and interpretation
- Targeted genetic testing for hereditary cancer (high‑depth NGS and genotyping)
- Combined chemical–genetic diagnostic panel development
- Design and management of genotype‑stratified and prospective cohort studies
Key Technologies
- Inductively coupled plasma mass spectrometry (ICP‑MS) for trace elements
- Targeted next‑generation sequencing (high‑depth amplicon panels)
- Multiplex probe‑based copy‑number analysis
- DNA methylation assays on urine sediment
News & Updates
Details about the extraordinary general meeting including agenda and legal information.
Details about the ordinary general meeting including agenda and legal information.
Information about patent applications and resolutions related to the company's research and development.
A scientific publication about the ATRIP gene mutation and its link to breast cancer risk, available in March 2023.
Patent Portfolio
8 foreign patents and 18 Polish patents granted, with ongoing patent applications.
Details about the extraordinary general meeting including agenda and legal information.
Details about the ordinary general meeting including agenda and legal information.
Information about patent applications and resolutions related to the company's research and development.
A scientific publication about the ATRIP gene mutation and its link to breast cancer risk, available in March 2023.
Patent Portfolio
8 foreign patents and 18 Polish patents granted, with ongoing patent applications.